Comparison of the functional properties of three different truncated thyroid hormone receptors identified in subjects with resistance to thyroid hormone.
The tau4 domain in the extreme carboxyl (C) terminal region of thyroid hormone receptor (TR) is important to transactivation. We identified three truncated TRbeta1s with 11 (F451X), 13 (E449X) and 16 (C446X) amino acid deletions within this domain in subjects with resistance to thyroid hormone (RTH). F451X and C446X were found in a 6-year-old Japanese girl and a 31-year-old American male, respectively, who had both severe mental retardation. E449X was identified in a 16-year-old Japanese boy with no remarkable clinical symptoms except for goiter. Transient expression study revealed that all three mutants had negligible T3 binding and transcriptional activities. Each mutant TRbeta1 exhibited not only very strong dominant negative activity against wild TRbeta1, but also marked silencing activity. Interestingly, the dominant negative activity and silencing activity were significantly stronger in F451X than in E449X and C446X (P < 0.05). Gel-shift experiments revealed no apparent differences in homodimer formations of wild-type or mutant TRbeta1 proteins and in heterodimer formations with retinoid X receptor (RXR). These observations indicate that the tau4 domain affects diverse TR functions, and that the region between 11 and 13 C-terminal amino acids influences ligand-independent TR functions, including dominant negative and silencing activities. The central nervous system involvement is not necessarily determined by the dominant negative potency of the mutant TRbeta1 and other environmental or genetic factors may influence the RTH manifestations.
Miyoshi
Y
Y
Department of Medicine and Clinical Science, Kyoto University School of Medicine, Sakyoku, Japan. ymiyoshi@mail.med.upenn.edu
Nakamura
H
H
Tagami
T
T
Sasaki
S
S
Dorin
R I
RI
Taniyama
M
M
Nakao
K
K
D000293:Adolescent; D000328:Adult; D000818:Animals; D001483:Base Sequence; D019556:COS Cells; D002648:Child; D004247:DNA / Q000235:genetics / Q000378:metabolism; D015342:DNA Probes / Q000235:genetics; D019281:Dimerization; D004351:Drug Resistance / Q000235:genetics / Q000502:physiology; D005260:Female; D006042:Goiter / Q000235:genetics / Q000503:physiopathology; D006801:Humans; D066298:In Vitro Techniques; D008607:Intellectual Disability / Q000235:genetics / Q000503:physiopathology; D008297:Male; D011988:Receptors, Thyroid Hormone / Q000737:chemistry / Q000235:genetics* / Q000502:physiology*; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D017384:Sequence Deletion; D018382:Thyroid Hormone Resistance Syndrome / Q000235:genetics* / Q000503:physiopathology*; D015533:Transcriptional Activation; D014162:Transfection; D014212:Tretinoin / Q000378:metabolism; D014284:Triiodothyronine / Q000378:metabolism
D015342:DNA Probes; D011988:Receptors, Thyroid Hormone; D011994:Recombinant Proteins; D014284:Triiodothyronine; D014212:Tretinoin; D004247:DNA